Phio Pharmaceuticals Corp. (PHIO): Cash & Equivalents
$21.03M
As of 2025-12-31
$13.00M
As of 2026-06-30
+15.2%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $21.03M | +290.8% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $5.38M | -36.6% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $8.49M | n/a | 2025-03-31, Balance as of period end |
| No annual figure between 2017-12-31 and 2023-12-31. | |||
| 2017-12-31 | $3.58M | -72.3% | 2018-03-26, Balance as of period end |
| 2016-12-31 | $12.91M | +152.2% | 2018-03-26, Balance as of period end |
| 2015-12-31 | $5.12M | -39.8% | 2017-03-30, Balance as of period end |
| 2014-12-31 | $8.50M | -25.4% | 2016-03-30, Balance as of period end |
| 2013-12-31 | $11.39M | +122.2% | 2015-03-30, Balance as of period end |
| 2012-12-31 | $5.13M | +919.3% | 2014-03-28, Balance as of period end |
| 2011-12-31 | $503.0K | n/a | 2014-03-28, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | 2025-12-31 | $21.03M | +290.8% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $2.13M | +53.1% |
| BriaCell Therapeutics Corp. (BCTX) | 2025-07-31 | $10.49M | n/m |
| Annovis Bio, Inc. (ANVS) | 2025-12-31 | $19.53M | +85.1% |
| Abvc Biopharma, Inc. (ABVC) | 2025-12-31 | $681.5K | +174.4% |
| Moleculin Biotech, Inc. (MBRX) | 2025-12-31 | $8.88M | +107.5% |
| Nexentis Technologies Inc. (NXTS) | 2025-12-31 | $3.83M | +99.3% |
| Quoin Pharmaceuticals Ltd. (QNRX) | 2025-12-31 | $3.82M | +5.4% |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | $578.0K | -22.0% |
Compare PHIO, EMMA, BCTX, ANVS side by side · Screen every company in Pharmaceutical Preparations ↗